New Seneca Partners Doubles Down on Vivos Therapeutics with $2.25M Investment
Event summary
- Vivos Therapeutics secured a $2.25 million private placement from an affiliate of New Seneca Partners.
- The deal includes the conversion of a previously announced $1.4 million bridge note, reflecting an original issue discount.
- Seneca affiliates have invested a total of $13.4 million in Vivos since 2024.
- The placement included common stock, warrants, and was priced at $1.34 per share.
- Proceeds will be used for general working capital.
The big picture
New Seneca Partners’ continued investment signals confidence in Vivos’s strategic pivot towards a vertically integrated model encompassing diagnostics and treatment for sleep apnea. The $13.4 million total investment underscores a belief that Vivos is undervalued, despite the challenges inherent in transitioning from a dentist-focused business to a broader healthcare provider network. This move highlights the growing trend of private equity firms backing specialized healthcare services companies focused on chronic disease management.
What we're watching
- Operational Efficiency
- The company's stated focus on optimizing operations in Las Vegas and Detroit, alongside managing legacy costs, will be critical to achieving the stated breakeven target by the end of 2026 and warrants close monitoring.
- Affiliation Model
- The success of Vivos’s shift towards a medical affiliation distribution model, as validated by Seneca’s continued investment, hinges on the ability to onboard new practices and integrate them effectively.
- Insurance Reimbursement
- The sustainability of the ‘in-network’ status recently achieved with commercial health insurance payers and Medicare will significantly impact revenue generation and requires ongoing vigilance.
Related topics